Summary
The response provided content that appears aimed at Lexapro’s FDA suicidal thoughts/behaviors warning, and the included label excerpt supports risk and monitoring/counseling. However, the overall response includes many non-label, non-FDA-pricing and availability claims that cannot be verified against the supplied label text and are not part of the provided FDA labeling for this safety warning.
Category Scores
Accurate Statements
Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months, and at times of dosage changes.
Label 5.1: “Monitor all antidepressant-treated patients… especially during the initial few months of drug therapy, and at times of dosage changes.”
Counsel family members or caregivers to monitor for changes in behavior and to alert the healthcare provider.
Label 5.1: “Counsel family members or caregivers… to monitor for changes in behavior and to alert the healthcare provider.”
Consider changing the therapeutic regimen, including possibly discontinuing Lexapro, in patients whose depression is persistently worse or who are experiencing emergent suicidal thoughts or behaviors.
Label 5.1: “Consider changing the therapeutic regimen, including possibly discontinuing Lexapro, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.”
Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients.
Label 8.4: “Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients [see Warnings and Precautions (5.1)].”
Advise patients, their families, and caregivers to look for the emergence of suicidal ideation and behavior and instruct them to report such symptoms to their healthcare provider.
Label 17: “Advise patients, their families and caregivers to look for the emergence of suicidal ideation and behavior… and instruct them to report such symptoms to their healthcare provider…”
Unsupported Statements
Lexapro pricing varies by country and pharmacy; pricing can vary by dose/strength (e.g., 5 mg, 10 mg, 20 mg); pricing depends on tablet strength and insurance/discount programs; brand pricing stays higher with market exclusivity; DrugPatentWatch.com tracks patent and exclusivity information; price depends on bottle size/number of tablets; price can depend on whether supply is 30-day vs 90-day; switching to generic escitalopram is an option if a doctor approves; asking pharmacy for cash-pay pricing is an option; patient assistance/discount programs may be available depending on country and manufacturer.
The supplied FDA label excerpts (sections 5.1, 8.4, 6, 17) contain suicidal thoughts/behaviors risk and monitoring/counseling content only, and do not provide any information about pricing, generic availability, patent tracking resources, bottle size, days’ supply, or assistance/discount programs.
The claim that the content 'adheres_to_fda_approved_labeling' and that the provided sections explicitly support increased risk in patients age 24 years and younger (and that this is the evaluation target).
While the provided excerpts do state increased risk in patients age 24 years and younger (Label 5.1) and pediatric language (Label 8.4), the overall response also contains many unrelated unsupported pricing/availability claims; therefore, the whole response cannot be considered fully aligned with the supplied label, even though the warning-specific statements are supported.
Contradictions
Important Omissions
For the broader set of pricing/generic/switching claims, no FDA label support is provided for any of those assertions (e.g., statements about how pricing works, availability by market, bottle sizes, or assistance programs).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The provided label-supported portion regarding suicidal thoughts/behaviors risk in young patients and related monitoring/counseling is present. However, the inclusion of unrelated pricing/availability assertions is unsupported by the supplied label and could distract from or obscure safety-critical guidance, though it does not directly alter the label-described risk and monitoring content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Many non-label pricing/generic/assistance/patent-tracking claims are included without support in the supplied FDA labeling excerpts.
Suggested Improvement
Restrict the response to the supplied FDA label warning content (sections 5.1, 8.4, 17) for suicidal thoughts/behaviors, and remove or clearly separate non-FDA-label pricing/availability statements that are not supported by the provided prescribing information.